Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (March 2025)
29 slides from Osteopore's investor presentation, March 2025
Slide 1: Investor Presentation
Investor Presentation MARCH 2025 ASX: OSX
Slide 2: Disclaimer
OSTEOPORE.COM Disclaimer This presentation has been prepared by Osteopore Limited Neither the Company, nor its related bodies corporate, of which are outside the control of the Company. and its related entities (the ÒCompanyÓ). It does not purport officers, their advisers, agents and employees accep
Slide 3: Introduction
OSTEOPORE.COM Introduction Osteopore Ltd. is a global medical technology OsteoporeÕs patented scaffolds are made using company commercialising products that enable a proprietary manufacturing technique that tissue regeneration across multiple therapeutic comprises a dissolvable polymer. areas. Our w
Slide 4: Vision, Mission and Goal
OSTEOPORE.COM Vision Be the most valuable regenerative medical technology company in the world Mission Harness our superior technology to become the standard of care globally for natural tissue regeneration Goal Improve clinical outcomes and patient quality of life 44
Slide 5: Our business segments
Our business segments OSTEOPORE.COM Craniofacial Aesthetic (Rhinoplasty) Orthopaedic Dental & OMF USD $1.1b global market (2022) USD $5.88b global market (2022) USD $48b global market (2022) USD $4.43b global market (2023) 8.3% CAGR (2023-2032) 7.3% CAGR (2023-2030) 5.3% CAGR (2023-2032) 6.9% CAGR (
Slide 6: Investment highlights
Investment highlights OSTEOPORE.COM 1# 3# Revenue Market Potential High market valuation with significant Generating growth opportunities. The Post-sales revenue-generating regenerative medicine market is regenerative medicine company. projected to reach A$120b by 2035. 2# 4# Pipeline Value-based In
Slide 7: Regenerative medicine
Regenerative medicine OSTEOPORE.COM Exciting market opportunity with growth potential Links to multiple High market valuation Value-based care technology sectors • In 2023, the global regenerative • Links the multi-billion-dollar • With the power to reduce drugs, medicine market was worth USD medtec
Slide 8: Breakthrough technology, regenerative products
Breakthrough technology, regenerative products OSTEOPORE.COM Unique technology Value proposition Multiple applications • Breakthrough technology that • WorldÕs first biomimetic Application areas: leverages 3D printing to • Craniofacial bioscaffold that dissolves enable bone regeneration naturally ov
Slide 9: Unlocking USD $1.9b in market potential
Unlocking USD $1.9b in market potential OSTEOPORE.COM Craniofacial & Neurosurgery Rhinoplasty Orthopaedic surgery Dental USD$385.3m USD$200m USD$986m USD$400m Off-the-shelf America Customised Europe In progress Asia Pacific Special Access South Korea Australia Middle East Africa Latin America * * Co
Slide 10: Leveraging 3D printing to create scaffolds that guide tissue regeneration
Leveraging 3D printing to create scaffolds that OSTEOPORE.COM guide tissue regeneration Biomimetic Cell Tissue Regenerative implants microstructure proliferation regeneration Osteopore is pushing the boundaries of 3D printing to develop and commercialise biomimetic microstructure that enables natura
Slide 11: Dramatically improving patient quality of life
Dramatically improving patient OSTEOPORE.COM 10 Quality of Life months Function restored Back to work Creating a step-change in patient Quality of Life after significant bone loss due to surgery Early PSI mineralisation 6 Initial osseous in-growth months Bone defect 20kg partial weight-bearing Bone
Slide 12: Our applications
Our applications OSTEOPORE.COM Aesthetics (Rhinoplasty) Patient-centred design Proven solutions in septal extension grafting Aesthetics (Rhinoplasty) Craniofacial Dental Orbital Surgery Orthopaedic Neurosurgery Proven solutions and Proven solutions in developing applications in orbital floor Dental/
Slide 13: Craniofacial
OSTEOPORE.COM Craniofacial Core business Craniotomy Orbital floor reconstruction Product Example Product Example Enables the complete restoration of patientsÕ Delivers structural support and consistent skull contours in post-craniotomy procedures bone regeneration for orbital floor fractures Now Obj
Slide 14: Aesthetic (Rhinoplasty)
Aesthetic (Rhinoplasty) OSTEOPORE.COM Core business Septal extension grafting Nasal tip plasty Product Example Product Example Provides structural support to achieve Adds projection to the nasal tip for a natural and long-term and aesthetically pleasing nose aesthetically pleasing augmentation augme
Slide 15: Orthopaedic
OSTEOPORE.COM Orthopaedic Core business Now Objectives • 135 cumulative implants • Commercialise in ASEAN and APAC with partners that have established distribution • 6+ years of clinical experience channels and customer relationship • Footprint in 5+ countries • Invest in Medical Education to grow p
Slide 16: Dental & OMF
OSTEOPORE.COM Dental & OMF Core business Socket preservation Guided bone regeneration Product Example Product Example Regenerate bone in socket to Semi-flexible membrane to facilitate dental implant placement maintain alveolar width and height Now Objectives • 580+ cumulative implants • Drive adopti
Slide 17: World-first surgeries, life-changing outcomes
World-first surgeries, life-changing outcomes OSTEOPORE.COM Cranial remodelling Facial and orbital Skull reconstruction floor reconstruction The cranial remodelling of a Skull reconstructed after a child with craniosynostosis Ð a The use of 3D bioabsorbable craniotomy Ð bone removed premature fusion
Slide 18: World-first surgeries, life-changing outcomes
World-first surgeries, life-changing outcomes OSTEOPORE.COM Segmental bone defect Post-cancer bone reconstruction Largest-ever construction of a segmental Post-cancer reconstruction of a 15cm tibia 2 bone defect 1 • Reconstruction saved leg from being amputated • Reconstruction of a 36cm tibia • The
Slide 19: Our global footprint – current and future
Our global footprint Ð current and future OSTEOPORE.COM 19
Slide 20: Delivering sustained commercial growth
Delivering sustained commercial growth OSTEOPORE.COM Annual Revenue in A$Õ000 3,000 • Consistent growth in annual revenue 2,811 2,500 • Record revenue in CY 2024: AUD $2.8M • High gross margin business >80% (CY 24) 1 2,217 2,000 1,692 1,500 1,505 1,000 1,113 * impact of COVID-19 500 - 1 Appendix 4E
Slide 21: Our business model and growth strategy
Our business model and growth strategy OSTEOPORE.COM Continuously review and strengthen distribution network to accelerate revenue growth Organic growth Obtain additional regulatory approval to expand sales (China, Japan) and register new products to access new markets and revenue (orthopaedic, dent
Slide 22: Our global strategy
Our global strategy OSTEOPORE.COM Partnership Sourcing and matching partners to our product segments to commercialise and distribute our products globally Regulatory approval Conducting pre-market testing and clinical trials to secure market approval in APAC, ASEAN, Greater China as well as EMEA and
Slide 23: Blue-sky outcomes
Blue-sky outcomes OSTEOPORE.COM Commercialising next-gen Strengthening rotator cuff Investing in future biologics and additives augmentation regenerative and prevention technologies Osteopore is collaborating Osteopore is collaborating with Osteopore initiates the with research organisations to Livi
Slide 24: Our leaders
Our leaders OSTEOPORE.COM Mark Leong Lim Yujing Executive Chairman Executive Director, CEO & CTO ACCA, ISCA, SID PhD Bioengineering (Singapore) Prof. Teoh Swee Hin Daniel Ow Hon. Michael Keenan Voon Shu Ning Ammar Hassanbhai Non-Executive Director Non-Executive Director Non-Executive Director Financ
Slide 25: Our advisors
Our advisors OSTEOPORE.COM Neurosurgery Orthopaedic R&D A/Prof. Andrew Chin Yuan Hui Dr. Rondhir Jithoo MD A/Prof. Yeo Tseng Tsai Clinical Asst. Prof. Hamid Razak Dr. James Tan MD Senior Consultant Hand and Dr. Henry Soeharno Tan Kim Cheng Neurosurgeon Neurosurgeon Consultant Orthopaedic Surgeon Ort
Slide 26: Why Osteopore?
Why Osteopore? OSTEOPORE.COM x De-risked profile Strong pedigree • Globally validated technology • Global leader in regenerative medicine • 120k successful cases and a growing sales pipeline • Leading-edge bioresorbable and biomimetic • Clear vision of profitability implants • Strong IP with patents
Slide 27: Why Osteopore?
Why Osteopore? OSTEOPORE.COM x Global opportunity Addressable market • Technology platform with potential lateral • 4 business units targeting a total expansion into regenerative medicine addressable market of ~USD $50b • Projected USD $532b regenerative medicine • High-impact collaborations to boos
Slide 28: Investment highlights
Investment highlights OSTEOPORE.COM 1# 3# De-risked Strong Pedigree & Profile Outcomes Globally validated technology, Global leader in regenerative 120K successful cases, growing medicine recognised for its world- sales and a clear profit vision 2# first surgeries and patient outcomes 4# Breakthroug
Slide 29: Contact details
Mark Leong Executive Chairman E: mark_leong@osteopore.com Lim Yujing Chief Executive Officer & Chief Technology Officer E: lim_yujing@osteopore.com Isaac Stewart Investor & Media Relations E: istewart@purple.au